Global Artificial-Heart Lung Machine Market - 2022-2029

Market Overview

Artificial-Heart Lung Machine market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 4.3% during the forecast period (2022-2029).

An artificial heart-lung machine is used in open-heart surgery to support the proper functioning of the heart and body during the surgery. The heart-lung machine contains a chamber that receives the blood from the body, oxygenates and transfers the blood to all parts of the body. The machine is connected to the patient with a series of tubes, which are then removed after the completion of the surgery when the heart and lungs resume their normal functions.

Market Dynamics

The major driving forces are the rising heart disease prevalence, the growing geriatric population, and technological advancements.

The increasing prevalence of cardiovascular disease and rising awareness of cardiopulmonary disease propel the global market growth.

The rising prevalence of cardiovascular diseases fuels the global artificial -heart-lung machine market. For instance, the data from the British Heart Foundation indicates that around 168,319 people died in 2020 because of CVD. Cardiovascular diseases are rising due to various factors, a few examples of which are the growing geriatric population, rising disposable income, changing lifestyles, smoking, and others; for instance, the world health organization estimated that in 2020, there were around 1 billion people aged 60 and above. It is estimated that by 2050 the geriatric population will reach 2.1 billion. In addition, tobacco consumption has claimed over 8 million deaths every year globally, of which nearly 7 million are because of the direct use of tobacco, while close to 1.2 million are as a result of non-smokers exposed to secondhand smoke.

The stringent regulations and lack of skilled professionals hinder the global artificial-heart lung machine market growth.

However, stringent regulations and the shortage of skilled healthcare professionals are expected to hamper the artificial-heart lung machine market growth.

Industry analysis.

The global artificial-heart lung machine market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, epidemiological analysis, Etc.

COVID-19 Impact Analysis

The outbreak has negatively affected the global market since various restrictions and regulations were forced to prevent the spread of the infection, making it difficult for people to perform different cardiac function diagnostic tests. Furthermore, the restrictions on transportation have led to the disruption of supply chain management; during the pandemic, many major surgeries were postponed or canceled, which badly impacted the global artificial-heart lung machine market.

Segment Analysis

The single roller pump artificial-heart lung machines are predicted to have a high demand during the forecast period (2022-2029).

The single roller pump is expected to dominate the global market during the forecast period (2022-2029) since the single roller pump provides more pulsatile blood circulation than the double roller pump. For instance, the single-roller pump contains a circular raceway in which a 360-degree loop of tubing is inserted. Single-roller pumps were used for CPB in the 1950s and early 1960s because they produced more pulsatility than conventional double-roller pumps. The double-roller pump consists of a 210-degree semicircular backing plate and two rollers with rotating arms set 180 degrees apart. When one roller ends its occlusive phase, the other has already begun its occlusive phase. Because one of the two rollers is always compressing the tubing, the double-roller pump generates a relatively nonpulsatile flow. Although the multiple-roller pump has been proposed for extracorporeal blood handling, it is not clinically available because it causes more hemolysis.

Geographical Analysis

North America is predicted to command the global Artificial-Heart Lung Machine market.

North America dominated the global artificial heart-lung machine market in 2021. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the increasing incidences of cardiovascular diseases, rapid technological advances, increasing awareness among the population, and the growing preference for minimally invasive procedures. The rising cardiovascular disease incidence is expected to drive the market over the forecast period. For instance, according to the CDC, every 34 seconds, a U.S. American dies because of cardiovascular disease; in 2020, 697,000 American deaths were caused by cardiovascular disease. Also, the headquarters of key market players in North America, such as SynCardia and Medtronic, ensure North America's dominance over the global market. Furthermore, the active intervention by the government, like the "Million Hearts" initiative by the U.S. government, to spread awareness about risks associated with cardiopulmonary diseases.

Competitive Landscape

The major players operating in the global artificial heart-lung machine market are LivaNova Plc, Getinge AB, Elite LifeCare, Nipro Corp, Braile Biomedica, Terumo Corporation, SynCardia, Medtronic, and MAQUET GmbH & Co. KG (Getinge group). The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the artificial heart-lung machine market globally. For instance, on Apr 08, 2022, LivaNova initiated a targeted commercial launch of the Essenz patient monitor for cardiopulmonary bypass procedures. Also, on July 21, 2022, Terumo India signed a new strategic commercial distribution partnership with Sensible Medical Innovations.

Medtronic, Plc.

Overview:

Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Product Portfolio:

The product portfolio of Medtronic, Plc. The product portfolio for artificial-heart lung machines contains CENTURY HEART LUNG MACHINE and THE QUANTUM PERFUSION SYSTEM.

The global artificial-heart lung machine market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.